NCT00802464View on ClinicalTrials.gov

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

January 12, 2009

Primary Completion Date

July 2, 2010

Study Completion Date

July 2, 2010

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Herpes zoster vaccine GSK1437173A

2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)

BIOLOGICAL

Placebo

2 vaccinations at Months 0 and 2 with placebo

Trial Locations (12)

15236

GSK Investigational Site, Pittsburgh

27612

GSK Investigational Site, Raleigh

28040

GSK Investigational Site, Marid

28222

GSK Investigational Site, Mahadahonda( Madrid

33024

GSK Investigational Site, Pembroke Pines

44122

GSK Investigational Site, Cleveland

85020

GSK Investigational Site, Phoenix

89130

GSK Investigational Site, Las Vegas

08817

GSK Investigational Site, Edison

500 01

GSK Investigational Site, Hradec Králové

08035

GSK Investigational Site, Barcelona

Unknown

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY